|
covid-19 |
39 |
|
sars-cov-2 |
33 |
|
mucosal immunity |
17 |
|
receptor binding domain |
16 |
|
ace2 |
13 |
|
inactivated vaccine |
13 |
|
rnai |
13 |
|
sace2 |
13 |
|
2′-o-methyltransferase |
11 |
|
live attenuated vaccine |
11 |
|
nsp16 |
11 |
|
sterilizing immunity |
11 |
|
t-cell response |
11 |
|
human neutralizing antibody |
10 |
|
lung injury |
10 |
|
nasal turbinate |
10 |
|
phage display |
10 |
|
upper respiratory tract |
10 |
|
immune protection |
9 |
|
neutralizing antibodies |
9 |
|
sars-cov-2 variants of concern |
9 |
|
acute infection |
8 |
|
b-cell suppression |
8 |
|
convalescent |
8 |
|
delns1-ncov-rbd laiv |
8 |
|
dendritic cell |
8 |
|
intranasal |
8 |
|
mitochondrial dysfunction |
8 |
|
phase-1 |
8 |
|
covid19 |
7 |
|
disease severity |
7 |
|
icu patient |
7 |
|
neutralizing antibody |
7 |
|
live-attenuated influenza-based vaccine |
6 |
|
memory t cell |
6 |
|
mitochondrial dysfunction (md) |
6 |
|
nasal prevention |
6 |
|
pd1-based dna vaccine |
6 |
|
t-cell functionality |
6 |
|
aids |
5 |
|
cd4 t cell |
5 |
|
hiv-1 |
5 |
|
nicotinamide mononucleotide |
5 |
|
t cell activation |
5 |
|
broadly neutralizing antibody |
4 |
|
cellular immune response |
4 |
|
chimpanzee adenovirus vector |
4 |
|
humoral immune response |
4 |
|
mrna vaccine |
4 |
|
omicron breakthrough infection |
4 |
|
prevention of xbb.1.5 transmission |
4 |
|
protective immunity |
4 |
|
sars-cov-2 vaccine |
4 |
|
single-dose immunization |
4 |
|
spike protein |
4 |
|
structural fitness of antibody |
4 |
|
cross-reactive |
3 |
|
elderly |
3 |
|
iccov |
3 |
|
pd-1-enhanced dna vaccine |
3 |
|
t cell |
3 |
|
35b5 |
2 |
|
antigenic shift |
2 |
|
dissociation |
2 |
|
glycan |
2 |
|
hiv |
2 |
|
immunotherapy |
2 |
|
monoclonal antibody |
2 |
|
neutralization |
2 |
|
omicron |
2 |
|
rbd |
2 |
|
t-cell differentiation |
2 |
|
tissue-resident memory t cell |
2 |
|
vaccine |
2 |
|
amyloid fibrils |
1 |
|
antiretrovirals |
1 |
|
antiviral |
1 |
|
bats |
1 |
|
bbb |
1 |
|
bowman-birk inhibitor |
1 |
|
cc chemokine |
1 |
|
ccr5 |
1 |
|
cd4 |
1 |
|
cd4 t cell + |
1 |
|
cd4/cd8 ratio |
1 |
|
cd8 activation |
1 |
|
coronavirus |
1 |
|
cynomolgus |
1 |
|
depletion |
1 |
|
drug-resistant hiv |
1 |
|
egcg |
1 |
|
evolution |
1 |
|
exosomes |
1 |
|
galnac |
1 |
|
hantaviruses |
1 |
|
hbmecs |
1 |
|
human cervical epithelial cells |
1 |
|
human intestinal epithelial cells |
1 |
|
ifn-stimulated genes |
1 |
|
ifn-β |
1 |
|
ifn-λ |
1 |
|
imjin virus |
1 |
|
immune activation |
1 |
|
interferon-stimulated genes |
1 |
|
interferons |
1 |
|
lymph nodes |
1 |
|
macaque |
1 |
|
macrophage |
1 |
|
macrophages |
1 |
|
microglia |
1 |
|
mitogenicity |
1 |
|
mx2 |
1 |
|
phylogeny |
1 |
|
recombination |
1 |
|
rodents |
1 |
|
sars |
1 |
|
sevi |
1 |
|
shiv |
1 |
|
shrews |
1 |
|
simian immunodeficiency virus |
1 |
|
siv |
1 |
|
soybean lectin |
1 |
|
tetherin |
1 |
|
thottapalayam virus |
1 |
|
tlr3 |
1 |
|
toll-like receptor 3 |
1 |
|
transmission |
1 |
|
viremia |
1 |
|
哈巴罗夫斯克病毒 (khabarovsk virus) |
1 |
|
汉坦病毒 (hantavirus) |
1 |
|
系统进化分析 (phylogenetic analysis) |
1 |
|
莫氏田鼠 ( microtus maximowixzii) |
1 |
